icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
n31eVHxABedeDdRf
Listen
